Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp (PROF) delivers innovative MRI-guided therapeutic solutions for prostate ablation, merging precision imaging with minimally invasive treatment. This news hub provides investors and healthcare professionals with timely updates on clinical advancements, regulatory milestones, and corporate developments shaping the future of image-guided therapies.
Access verified information on PROF's TULSA-PRO system adoption, partnership announcements, and financial performance. Our curated news collection features earnings reports, research publications, and market analysis to help stakeholders track the company's progress in advancing non-invasive treatment options.
Key coverage areas include FDA clearances, clinical trial outcomes, technology enhancements, and strategic collaborations. Stay informed about developments in therapeutic ultrasound applications and the growing adoption of closed-loop thermal control systems in urology practices worldwide.
Bookmark this page for direct access to primary source materials and expert commentary on PROF's role in transforming prostate cancer treatment paradigms through cutting-edge medical device innovation.
Profound Medical Corp. announced its first quarter 2024 financial results and issued full-year 2024 revenue guidance. The Company reported revenue of $1.91 million for Q1 2024, with 3% growth from the same period last year. Operating expenses increased by 9% to $8.8 million. Net loss for Q1 2024 was $6.2 million. The Company expects full-year 2024 revenue to range from $11.0 million to $12.0 million, representing significant growth. Profound had cash of $41.2 million and 24,428,899 common shares outstanding as of March 31, 2024.
Profound Medical Corp.'s TULSA procedure is gaining recognition as a mainstream treatment for prostate diseases, with 25 scientific research presentations this year alone. The clinical evidence showcases TULSA's efficacy in treating a diverse range of patients with localized prostate cancer and/or BPH. The company's CEO, Arun Menawat, highlights the positive outcomes from top medical centers worldwide, positioning TULSA as a leading treatment modality.
FAQ
What is the current stock price of Profound Med (PROF)?
What is the market cap of Profound Med (PROF)?
